肺舒合剂治疗支气管哮喘急性发作期疗效观察

Feishuheji Treatment Bronchial Asthma Acute Attack Curative Effect Observation

目的:观察肺舒合剂治疗支气管哮喘急性发作期的临床疗效。方法:将146例支气管哮喘患者随机分为2组。对照组给予西医常规治疗,治疗组加服肺舒合剂,疗程2周。结果:治疗组总控显率(临床控制+显效)为67.12%,总有效率94.52%,明显优于对照组的45.20%,78.08%(P<0.05)。肺功能第1s用力呼气容积(FEV1)、FEV1/预计值%和呼气峰流速(PEF)均有改善,治疗前后比较差异有显著性(FEV1,P<0.01,FEV1%和PEF,P<0.05),治疗后组间比较有显著性差异(P<0.05)。结论:肺舒合剂对支气管哮喘急性发作期的治疗效果显著。

Objective： Observation Feishuheji treatment bronchial tube asthma acute attackclinical curative effect. Method： Stochastically divides into 2 groups 146 examples bronchial tubesasthma patient. The comparison group gives the western medicine convention treatment,treatment group Canada takes Feishubeji, treatment course 2 weeks. Result： The treatment group always controls revealing rate is 67.12%, the total effectiveness 94.52%, obviously surpasses the comparison group 45.20% ,78.08% （ P 〈 0.05）. Around the treatment compares has the remarkable difference（ FEV1 , P 〈 0.01, FEV1 % 和 PEF, P 〈 0.05 ）, After the treatment the group compares has the remarkable difference （ P 〈 0.05 ）. Conclusion： The Feishuheji is remarkable to the bronchial asthma attack treatment result.